Abcellera Biologics

$30.27
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.44 (-4.79%) Today
+$1.66 (+5.80%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ABCL and other stocks, options, and ETFs commission-free!

About ABCL

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada. The listed name for ABCL is AbCellera Biologics Inc. Common Shares.

CEO
Carl Lars G. Hansen
Employees
107
Headquarters
Vancouver, British Columbia
Founded
2012
Market Cap
9.02B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
858.58K
High Today
$31.74
Low Today
$26.16
Open Price
$30.53
Volume
1.79M
52 Week High
$71.91
52 Week Low
$26.16

ABCL Earnings

Q4 FY20
Estimated
— per share
Actual
Available Mar 29, After Hours

You May Also Like

SLQD
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure